The team at Mills & Reeve LLP advises a varied client base of medical research charities, government bodies and fast-growing biotech and pharmaceutical companies, and the practice has ample experience in advising on tax, real estate, and IP matters. James Fry heads up the practice, often assisting clients with a broad range of contractual commercial issues. Fry also has broad expertise spanning research and technology collaborations, in addition to advertising and product classification work.

Legal 500 Editorial commentary

Key clients

  • GSK
  • Illumina
  • CMR Surgical
  • Neurocrine Biosciences
  • F-star Therapeutics
  • Sapphiros
  • NRG Therapeutics
  • PhoreMost
  • Redx Pharma
  • Calypso Biotech
  • CMR Surgical
  • Sanger Institute
  • Wren Therapeutics
  • Transition Bio
  • MD Orthopaedics
  • Haleon
  • Kadans
  • Sphere Fluidics

Work highlights

  • Advising GSK on the divestment of Haleon plc and the cloning and renegotiation of commercial contracts (a mix of technology contracts, MSAs etc.).
  • Advised F-star on its licence and collaboration agreement with Takeda. The agreement, which grants licences to Takeda of F-star’s proprietary platform IP relating to the generation of bi-specific antibodies, will facilitate research towards the development of a next generation immuno-oncology bispecific antibody.
  • Represented MDO in the opposition of an application for a conflicting trade mark by a company associated with a former distributor.

Lawyers

Practice head

The lawyer(s) leading their teams.

James Fry